메뉴 건너뛰기




Volumn 25, Issue 6, 2013, Pages 683-689

Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

Author keywords

fetoprotein; biomarkers; des carboxy prothrombin; hepatocellular carcinoma; sorafenib

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; SORAFENIB;

EID: 84877011264     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835d913b     Document Type: Article
Times cited : (65)

References (33)
  • 1
    • 0033503797 scopus 로고    scopus 로고
    • Intrahepatic recurrence after curative resection of hepatocellular carcinoma: Long-term results of treatment and prognostic factors
    • Poon R, Fan S, Lo C, Wang J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216-222.
    • (1999) Ann Surg , vol.229 , pp. 216-222
    • Poon, R.1    Fan, S.2    Lo, C.3    Wang, J.4
  • 2
    • 33846631323 scopus 로고    scopus 로고
    • Radiofrequency ablation of hepatocellular carcinoma: Correlation between local tumor progression after ablation and ablative margin
    • Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR 2007; 188:480-488.
    • (2007) AJR , vol.188 , pp. 480-488
    • Nakazawa, T.1    Kokubu, S.2    Shibuya, A.3    Ono, K.4    Watanabe, M.5    Hidaka, H.6
  • 3
    • 40149087561 scopus 로고    scopus 로고
    • Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: Risk factors and patterns
    • Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol 2008; 43:71-78.
    • (2008) J Gastroenterol , vol.43 , pp. 71-78
    • Okuwaki, Y.1    Nakazawa, T.2    Shibuya, A.3    Ono, K.4    Hidaka, H.5    Watanabe, M.6
  • 4
    • 72049103667 scopus 로고    scopus 로고
    • Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma
    • Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J, et al. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma. Am J Gastroenterol 2009; 104:2747-2753.
    • (2009) Am J Gastroenterol , vol.104 , pp. 2747-2753
    • Okuwaki, Y.1    Nakazawa, T.2    Kokubu, S.3    Hidaka, H.4    Tanaka, Y.5    Takada, J.6
  • 5
    • 77749298647 scopus 로고    scopus 로고
    • Liver cancer study group of Japan overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: Propensity score analysis
    • Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, et al. Liver cancer study group of Japan overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR 2010; 194:830-837.
    • (2010) AJR , vol.194 , pp. 830-837
    • Takayasu, K.1    Arii, S.2    Ikai, I.3    Kudo, M.4    Matsuyama, Y.5    Kojiro, M.6
  • 6
    • 0036682065 scopus 로고    scopus 로고
    • Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases
    • Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95:588-595.
    • (2002) Cancer , vol.95 , pp. 588-595
    • Ando, E.1    Tanaka, M.2    Yamashita, F.3    Kuromatsu, R.4    Yutani, S.5    Fukumori, K.6
  • 7
    • 41549135296 scopus 로고    scopus 로고
    • Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels
    • Nakazawa T, Adachi S, Kitano M, Isobe Y, Kokubu S, Hidaka H, et al. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. Oncology 2007; 73:90-97.
    • (2007) Oncology , vol.73 , pp. 90-97
    • Nakazawa, T.1    Adachi, S.2    Kitano, M.3    Isobe, Y.4    Kokubu, S.5    Hidaka, H.6
  • 9
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebocontrolled trial
    • Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009; 10:25-34.
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.L.1    Kang, Y.K.2    Chen, Z.3    Tsao, C.J.4    Qin, S.5    Kim, J.S.6
  • 10
    • 4944249117 scopus 로고    scopus 로고
    • BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    • Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
    • (2004) Cancer Res , vol.64 , pp. 7099-7109
    • Wilhelm, S.M.1    Carter, C.2    Tang, L.3    Wilkie, D.4    McNabola, A.5    Rong, H.6
  • 12
    • 47649105803 scopus 로고    scopus 로고
    • Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma
    • Toyoda H, Kumada T, Osaki Y, Oka H, Kudo M. Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol Res 2007; 37:S166-S171.
    • (2007) Hepatol Res , vol.37
    • Toyoda, H.1    Kumada, T.2    Osaki, Y.3    Oka, H.4    Kudo, M.5
  • 13
    • 60049099362 scopus 로고    scopus 로고
    • High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma
    • Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115:571-580.
    • (2009) Cancer , vol.115 , pp. 571-580
    • Kobayashi, M.1    Ikeda, K.2    Kawamura, Y.3    Yatsuji, H.4    Hosaka, T.5    Sezaki, H.6
  • 14
    • 58749090909 scopus 로고    scopus 로고
    • New utility of an old marker: Serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy
    • Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27:446-452.
    • (2009) J Clin Oncol , vol.27 , pp. 446-452
    • Chan, S.L.1    Mo, F.K.2    Johnson, P.J.3    Hui, E.P.4    Ma, B.B.5    Ho, W.M.6
  • 15
    • 84355167145 scopus 로고    scopus 로고
    • Rapid regression of advanced hepatocellular carcinoma associated with elevation of desgamma-carboxy prothrombin after short-term treatment with sorafenib-A report of two cases
    • Nakazawa T, Hidaka H, Shibuya A, Koizumi W. Rapid regression of advanced hepatocellular carcinoma associated with elevation of desgamma-carboxy prothrombin after short-term treatment with sorafenib-a report of two cases. Case Rep Oncol 2010; 3:298-303.
    • (2010) Case Rep Oncol , vol.3 , pp. 298-303
    • Nakazawa, T.1    Hidaka, H.2    Shibuya, A.3    Koizumi, W.4
  • 16
    • 77957559384 scopus 로고    scopus 로고
    • Early alphafetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
    • Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alphafetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116:4590-4596.
    • (2010) Cancer , vol.116 , pp. 4590-4596
    • Shao, Y.Y.1    Lin, Z.Z.2    Hsu, C.3    Shen, Y.C.4    Hsu, C.H.5    Cheng, A.L.6
  • 17
    • 79551521168 scopus 로고    scopus 로고
    • Early a-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    • Kim BK, Ahn SH, Seong JS, Park JY, Kim do Y, Kim JK, et al. Early a-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int 2011; 31:369-376.
    • (2011) Liver Int , vol.31 , pp. 369-376
    • Kim, B.K.1    Ahn, S.H.2    Seong, J.S.3    Park, J.Y.4    Kim Do, Y.5    Kim, J.K.6
  • 18
    • 80051745537 scopus 로고    scopus 로고
    • Des-g-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma
    • Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, et al. Des-g-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 2011; 29:321-325.
    • (2011) Dig Dis , vol.29 , pp. 321-325
    • Ueshima, K.1    Kudo, M.2    Takita, M.3    Nagai, T.4    Tatsumi, C.5    Ueda, T.6
  • 19
    • 81555231534 scopus 로고    scopus 로고
    • Early decrease in a-fetoprotein, but not des-g-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma
    • Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hoshioka T, et al. Early decrease in a-fetoprotein, but not des-g-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 2011; 81:251-258.
    • (2011) Oncology , vol.81 , pp. 251-258
    • Kuzuya, T.1    Asahina, Y.2    Tsuchiya, K.3    Tanaka, K.4    Suzuki, Y.5    Hoshioka, T.6
  • 20
    • 34249322375 scopus 로고    scopus 로고
    • Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13772 patients in Japan
    • Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13772 patients in Japan. Ann Surg 2007; 245:909-922.
    • (2007) Ann Surg , vol.245 , pp. 909-922
    • Minagawa, M.1    Ikai, I.2    Matsuyama, Y.3    Yamaoka, Y.4    Makuuchi, M.5
  • 21
    • 44449085884 scopus 로고    scopus 로고
    • Panel of experts in HCC-design clinical trials: Design and endpoints of clinical trials in hepatocellular carcinoma
    • Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Panel of experts in HCC-design clinical trials: design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.
    • (2008) J Natl Cancer Inst , vol.100 , pp. 698-711
    • Llovet, J.M.1    Di Bisceglie, A.M.2    Bruix, J.3    Kramer, B.S.4    Lencioni, R.5    Zhu, A.X.6
  • 23
    • 77349102071 scopus 로고    scopus 로고
    • Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
    • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60.
    • (2010) Semin Liver Dis , vol.30 , pp. 52-60
    • Lencioni, R.1    Llovet, J.M.2
  • 24
    • 67651165187 scopus 로고    scopus 로고
    • Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study
    • Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10:794-800.
    • (2009) Lancet Oncol , vol.10 , pp. 794-800
    • Faivre, S.1    Raymond, E.2    Boucher, E.3    Douillard, J.4    Lim, H.Y.5    Kim, J.S.6
  • 25
    • 67649946279 scopus 로고    scopus 로고
    • Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma; A phase II study
    • Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma; a phase II study. J Clin Oncol 2009; 27:3027-3035.
    • (2009) J Clin Oncol , vol.27 , pp. 3027-3035
    • Zhu, A.X.1    Sahani, D.V.2    Duda, D.G.3    Di Tomaso, E.4    Ancukiewicz, M.5    Catalano, O.A.6
  • 26
    • 47649124110 scopus 로고    scopus 로고
    • Clinical significance of alpha-fetoprotein: Involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma
    • Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H, et al. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23:e189-e197.
    • (2008) J Gastroenterol Hepatol , vol.23
    • Mitsuhashi, N.1    Kobayashi, S.2    Doki, T.3    Kimura, F.4    Shimizu, H.5    Yoshidome, H.6
  • 27
    • 36549061592 scopus 로고    scopus 로고
    • Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan
    • Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38:37-51.
    • (2008) Hepatol Res , vol.38 , pp. 37-51
    • Makuuchi, M.1    Kokudo, N.2    Arii, S.3    Futagawa, S.4    Kaneko, S.5    Kawasaki, S.6
  • 28
    • 78651317489 scopus 로고    scopus 로고
    • AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC
    • Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010; 45:1272-1282.
    • (2010) J Gastroenterol , vol.45 , pp. 1272-1282
    • Yamamoto, K.1    Imamura, H.2    Matsuyama, Y.3    Kume, Y.4    Ikeda, H.5    Norman, G.L.6
  • 29
    • 74549217434 scopus 로고    scopus 로고
    • Hypoxiainduced des-gamma-carboxy prothrombin production in hepatocellular carcinoma
    • Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Hypoxiainduced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2010; 36:161-170.
    • (2010) Int J Oncol , vol.36 , pp. 161-170
    • Murata, K.1    Suzuki, H.2    Okano, H.3    Oyamada, T.4    Yasuda, Y.5    Sakamoto, A.6
  • 30
    • 0024306506 scopus 로고
    • Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin
    • Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin. Cancer Res 1989; 49:6493-6497.
    • (1989) Cancer Res , vol.49 , pp. 6493-6497
    • Liebman, H.A.1
  • 31
    • 33644693140 scopus 로고    scopus 로고
    • Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma
    • Uehara S, Gotoh K, Handa H, Tomita H, Senshuu M. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005; 20:1545-1552.
    • (2005) J Gastroenterol Hepatol , vol.20 , pp. 1545-1552
    • Uehara, S.1    Gotoh, K.2    Handa, H.3    Tomita, H.4    Senshuu, M.5
  • 32
    • 70449579247 scopus 로고    scopus 로고
    • Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma
    • Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2009; 35:1005-1014.
    • (2009) Int J Oncol , vol.35 , pp. 1005-1014
    • Murata, K.1    Suzuki, H.2    Okano, H.3    Oyamada, T.4    Yasuda, Y.5    Sakamoto, A.6
  • 33
    • 84856082759 scopus 로고    scopus 로고
    • Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: A case report
    • Okuwaki Y, Nakazawa T, Hidaka H, Shibuya S, Koizumi W. Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. J Med Case Rep 2012; 6:38.
    • (2012) J Med Case Rep , vol.6 , pp. 38
    • Okuwaki, Y.1    Nakazawa, T.2    Hidaka, H.3    Shibuya, S.4    Koizumi, W.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.